• About
  • Licensing
  • Podcasting
  • Contact

AudioMedica.com

Medical News Interviews

  • Public Health
  • Oncology
  • Cardiovascular
  • General Medicine

Audio Journal of Oncology in Advance – March 1st, 2008

0
  • by alexperjescuadmin
  • in Oncology
  • — 4 Mar, 2008
Audio Journal of Oncology in Advance - March 1st, 2008
AudioMedica News
Audio Journal of Oncology in Advance - March 1st, 2008
Audio Journal of Oncology in Advance - March 1st, 2008
00:00 /
RSS Feed
Share
Link
Embed
//-->//>' class="input-embed input-embed-412"/>

Volume 16 Number 5 (March 1st, 2008) reporting from:
4th European Congress on Hematologic Malignancies (February 22-24, 2008, Paris)
Gastrointestinal Cancers Symposium (January 25-27, 2008, Orlando)
American Society of Hematology Annual Meeting (December 8-11, 2007 Atlanta)

Richard Stone
Richard Stone
George Canellos
George Canellos

Dasatinib: Durable Responses in Chronic Myeloid Leukemia

Richard Stone, Dana-Farber Cancer Institute, Boston
COMMENT: George Canellos, Dana-Farber Cancer Institute, Boston
Data released at the ASH conference show that dasatinib has given durable responses in patients with chronic phase chronic myeloid leukemia for whom imatinib has failed, or who cannot tolerate imatinib. In Atlanta Richard Stone discussed his findings with Derek Thorne, who then asked George Canellos to reflect on them.

Audio Journal of Oncology in Advance - March 1st, 2008

Anton Hagenbeek
Anton Hagenbeek
George Canellos
George Canellos

Ibritumomab Benefits Patients With Follicular Lymphoma

Anton Hagenbeek, University of Utrecht
COMMENT: George Canellos, Dana-Farber Cancer Institute, Boston
In patients with advanced-stage follicular non-Hodgkin’s lymphoma the radiolabeled antibody ibritumomab tiuxetan prolonged progression-free survival, according to a study reported at the ASH meeting. Sarah Maxwell spoke to the author Anton Hagenbeek. George Canellos put the data into context.

Charles Hsu
Charles Hsu
Robert Mayer
Robert Mayer

Adjuvant Chemoradiotherapy: Sizable Gains In the Treatment of Pancreas Cancer

Charles Hsu, Johns Hopkins University, Baltimore
COMMENT: Robert Mayer, Dana-Farber Cancer Institute
Patients with resectable pancreas cancer lived longer when treated with adjuvant radiation plus chemotherapy, according to a study reported at the gastrointestinal cancers conference in Orlando. Charles Hsu talked with Peter Goodwin about their findings; Robert Mayer assessed the work.

Pierre Fenaux
Pierre Fenaux

Azacitidine New Standard In High Risk Myelodysplastic Syndromes

Pierre Fenaux, Hôpital Avicenne, Paris
Phase III study results presented at ASH found the hypomethylating agent azacitidine was best for patients with high-risk MDS. Pierre Fenaux gave the details to Derek Thorne, who also heard from George Canellos.

Bart Barlogie
Bart Barlogie

Total Therapy Possible Cure For Multiple Myeloma?

Bart Barlogie, University of Arkansas, Little Rock
The total therapy clinical studies of multiple myeloma reported promising findings to the Hematologic Malignancies Congress in Paris. Bart Barlogie talked with Peter Goodwin about the new data from melphalan-induced tandem autologous transplants with additional thalidomide or bortezomib therapy.



LISTEN

[audio:https://www.audiomedica.com/podcasting/oncology/080301ajoiaPODCAST.mp3]

To subscribe to the ASCO Audio Journal of Oncology podcast please go to ASCO Audio Journal of Oncology in Advance Presentations or click here.
Share

Tags: chemoconferencegastrointestinalhematologicmyelodysplasticmyeloidmyelomapancreasradiationsymposiumtransplanttreatment

You may also like...

  • Audio Journal of Oncology in Advance – March 1st, 2007 Audio Journal of Oncology in Advance – March 1st, 2007 2 Mar, 2007
  • Oncology Times Broadcast News with the Audio Journal of Oncology – Insulin-Like Growth Factor Inhibition In Lung Cancer Oncology Times Broadcast News with the Audio Journal of Oncology – Insulin-Like Growth Factor Inhibition In Lung Cancer 6 Apr, 2009
  • Jan Burger New drug looks very promising in high risk chronic lymphocytic leukaemia 11 Dec, 2012

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

  • Previous story Radio-Labelled Antibodies: Big Benefits in Follicular Lymphoma?
  • Next story Audio Journal of Oncology in Advance – March 15th, 2008
  • News

    • Mandeep Mehra MDCOVID-19 Co-Morbidity Risks Quantified from Three Continents SurveyMay 28, 2020
    • Ultrahypofractionated Radiation Just As Effective for Prostate CancerUltrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
  • Related interviews

    • Ibrutinib: New Frontline Standard for Chronic…
    • Genomic-led AML Clinical Decision Making Within Seven Days
    • Microbiome Diversity Key To Survival After…
    • New Front Line Standard for Older Patients with…
    • Pembrolizumab: No Survival Gains Second Line In…
  • Home
  • Oncology
  • Audio Journal of Oncology in Advance – March 1st, 2008

© Copyright 2021 AudioMedica.com. Typegrid Theme by WPBandit.